Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations
Abstract A study to determine the impact of cyclosporine (Neoral), an inhibitor of P‐gp, on the pharmacokinetics of pralsetinib (trade name GAVRETO®) was conducted in 15 healthy adult volunteers. A single 200 mg dose of pralsetinib was administered orally alone and in combination with cyclosporine w...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Wiley
2024-06-01
|
| Sraith: | Clinical and Translational Science |
| Rochtain ar líne: | https://doi.org/10.1111/cts.13818 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|